Ascletis Pharma, Inc.

Detailed Description

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a protease inhibitor for the treatment of hepatitis C virus (HCV); Pegasys, an interferon receptor for the treatment of chronic Hepatitis B; and Ravidasvir, a NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B; ASC40, a fatty acid synthase inhibitor, which has completed Phase II clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); ASC41, a thyroid hormone receptor beta agonist, which has completed Phase Ib clinical trials for the treatment of NASH; and ASC42, a Farnesoid X Receptor agonist. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIa clinical trial to treat HIV; and ASC21, a NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of Covid-19, hepatitis B virus, and NASH. The company was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.